{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:33:20Z","timestamp":1783528400871,"version":"3.55.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/rlu.0b013e3182814ac1","type":"journal-article","created":{"date-parts":[[2013,2,14]],"date-time":"2013-02-14T07:33:45Z","timestamp":1360827225000},"page":"188-194","source":"Crossref","is-referenced-by-count":46,"title":["Dosimetric Analyses of Kidneys, Liver, Spleen, Pituitary Gland, and Neuroendocrine Tumors of Patients Treated With 177Lu-DOTATATE"],"prefix":"10.1097","volume":"38","author":[{"given":"Santosh Kumar","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhas","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Thakral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekhar","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210204","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0969-8043(98)00023-2","article-title":"Radiation dosimetry in nuclear medicine.","volume":"50","author":"Stabin","year":"1999","journal-title":"Appl Radiat Iso"},{"key":"R2-5-20210204","first-page":"3S","article-title":"The MIRD perspective 1999.","volume":"40","author":"Howell","year":"1999","journal-title":"J Nucl Med"},{"key":"R3-5-20210204","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/1097-0142(19940201)73:3+<905::AID-CNCR2820731324>3.0.CO;2-K","article-title":"Radiation dosimetry for radioimmunotherapy: an overview of current capabilities and limitations.","volume":"73","author":"Fisher","year":"1994","journal-title":"Cancer"},{"key":"R4-5-20210204","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.apradiso.2006.09.011","article-title":"On the preparation of a therapeutic dose of Lu-177 labeled DOTA-TATE using indigenously produced Lu-177 in medium flux reactor.","volume":"65","author":"Das","year":"2007","journal-title":"Appl Radiat Isot"},{"key":"R5-5-20210204","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1089\/cbr.2005.20.92","article-title":"The LundADose method for planar image activity quantification and absorbed-dose assessment in radionuclide therapy.","volume":"20","author":"Sjogreen","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"key":"R6-5-20210204","first-page":"37S","article-title":"MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates.","volume":"40","author":"Siegel","year":"1999","journal-title":"J Nucl Med"},{"key":"R7-5-20210204","first-page":"538","article-title":"MIRDOSE: personal computer software for internal dose assessment in nuclear medicine.","volume":"37","author":"Stabin","year":"1996","journal-title":"J Nucl Med"},{"key":"R8-5-20210204","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1259\/0007-1285-62-740-679","article-title":"The linear-quadratic formula and progress in fractionated radiotherapy.","volume":"62","author":"Fowler","year":"1989","journal-title":"Br J Radiol"},{"key":"R9-5-20210204","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2967\/jnumed.108.053173","article-title":"MIRD pamphlet no. 20: the effect of model assumptions on kidney dosimetry and response-implications for radionuclide therapy.","volume":"49","author":"Wessels","year":"2008","journal-title":"J Nucl Med"},{"key":"R10-5-20210204","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1089\/cbr.2011.0965","article-title":"Comparison of I-131 radioimmunotherapy tumor dosimetry: unit density sphere model versus patient-specific Monte Carlo calculations.","volume":"26","author":"Howard","year":"2011","journal-title":"Cancer Biother Radiopharm"},{"key":"R11-5-20210204","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","article-title":"Radiolabeled somatostatin analog Lu-177 DOTA0,Tyr3 DOTATATE in Patients with endocrine gastroenteropancreatic tumors.","volume":"23","author":"Kwekkeboom","year":"2005","journal-title":"J Clin Oncol"},{"key":"R12-5-20210204","first-page":"2002","article-title":"Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide.","volume":"37","author":"Andersson","year":"1996","journal-title":"J Nucl Med"},{"key":"R13-5-20210204","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","article-title":"Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.","volume":"10","author":"Krenning","year":"1999","journal-title":"Ann Oncol"},{"key":"R14-5-20210204","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00259-006-0355-4","article-title":"Peptide receptor radionuclide therapy with Lu-177 DOTATATE in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin.","volume":"34","author":"Van Essen","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-5-20210204","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s002590100490","article-title":"Receptor mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide.","volume":"28","author":"Paganelli","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"R16-5-20210204","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of 90Y-DOTA-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.","volume":"12","author":"Waldherr","year":"2001","journal-title":"Ann Oncol"},{"key":"R17-5-20210204","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with In-DTPAoctreotide: the Rotterdam experience.","volume":"32","author":"Valkema","year":"2002","journal-title":"Semin Nucl Med"},{"key":"R18-5-20210204","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10967-005-0920-5","article-title":"Radionuclides used for therapy and suggestion for new candidates.","volume":"266","author":"Kling","year":"2005","journal-title":"J Radioanal Nucl Chem"},{"key":"R19-5-20210204","first-page":"1919","article-title":"Radiation dosimetry for indium-111-pentetrotide.","volume":"38","author":"Stabin","year":"1997","journal-title":"J Nucl Med"},{"key":"R20-5-20210204","first-page":"87","article-title":"Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors.","volume":"31","author":"Bal","year":"2010","journal-title":"Trop Gastroenterol"},{"key":"R22-5-20210204","first-page":"359","article-title":"Clinical aspects of radiation nephropathy cancer.","volume":"19","author":"Breitz","year":"2004","journal-title":"Biother Radiopharm"},{"key":"R23-5-20210204","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2967\/jnumed.111.098665","article-title":"Reduction of renal uptake of radiolabeled DOTATATE by amifostine coadministration.","volume":"53","author":"Melis","year":"2012","journal-title":"J Nucl Med"},{"key":"R24-5-20210204","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00259-003-1117-1","article-title":"86Y-DOTA0-D-phe1-Tyr-octreotide (SMT 487)a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acide co-infusion.","volume":"30","author":"Jamar","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R25-5-20210204","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/cncr.24796","article-title":"Lu-177 DOTA0,Tyr3 DOTATATE therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy.","volume":"15","author":"Garkavij","year":"2010","journal-title":"Cancer"},{"key":"R26-5-20210204","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s002590100574","article-title":"Lu-177 DOTA0Tyr3DOTATATE: comparison with 111In-DTPA0octreotide in patients.","volume":"28","author":"Kwekkeboom","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"R27-5-20210204","first-page":"S102","article-title":"Dosimetry in patients undergoing Lu-177 DOTATATE therapy with indications for 90Y-DOTATATE.","volume":"33","author":"Cremonesi","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R28-5-20210204","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00259-009-1216-8","article-title":"Individualises dosimetry in patients undergoing therapy with Lu-177 DOTA-D-phel-Tyr3-DOTATATE.","volume":"37","author":"Sandstrom","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R29-5-20210204","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1089\/cbr.2006.325","article-title":"Results of individual patient dosimetry in peptide receptor radionuclide therapy with Lu-177 DOTA-TATE and Lu-177 DOTA-NOC.","volume":"22","author":"Wehrmann","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"R31-5-20210204","first-page":"83S","article-title":"Long-term follow-up renal function after peptide receptor radiation therapy (PRRT) with 90Y-DOTA0,Tyr3 octreotide and Lu-177 DOTA0,Tyr3DOTATATE.","volume":"46","author":"Valkema","year":"2005","journal-title":"J Nucl Med"},{"key":"R32-5-20210204","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-002-1023-y","article-title":"Receptor-mediated radionuclide therapy with Y-90 DOTATOC in association with amino acid infusion: a phase I study.","volume":"30","author":"Bodei","year":"2003","journal-title":"Eur J Nucl Med Imaging"},{"key":"R33-5-20210204","first-page":"1310","article-title":"Treatment with Lu-177 DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.","volume":"46","author":"Forrer","year":"2005","journal-title":"J Nucl Med"},{"key":"R34-5-20210204","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00259-006-0232-1","article-title":"Long-term toxicity of (177) Lu-DOTA (0),Tyr (3)DOTATATE in rats.","volume":"34","author":"Rolleman","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R35-5-20210204","first-page":"99S","article-title":"Patient-specific dosimetry in predicting renal toxicity with Y-90 DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.","volume":"46","author":"Barone","year":"2005","journal-title":"J Nucl Med"},{"key":"R36-5-20210204","first-page":"134","article-title":"Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy.","volume":"48","author":"Konijnenberg","year":"2007","journal-title":"J Nucl Med"},{"key":"R37-5-20210204","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","article-title":"Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTANOC and Lu-177 DOTATATE: the role of associated risk factors.","volume":"35","author":"Bodei","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R38-5-20210204","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","article-title":"Cisplatin Nephrotoxicity: a review.","volume":"334","author":"Yao","year":"2007","journal-title":"Am J Med Sci"},{"key":"R39-5-20210204","first-page":"1315","article-title":"Crucial role for somatostatin receptor subtype 2 in determining the uptake of 111In-DTPA-D-Phe1octreotide in somatostatin receptor-positive organs.","volume":"44","author":"Hofland","year":"2003","journal-title":"J Nucl Med"},{"key":"R40-5-20210204","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation.","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R41-5-20210204","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1200\/JCO.2011.37.2151","article-title":"Cohort study of somatostatin-based radiopeptide therapy with (90)Y-DOTA-TOC versus (90)Y-DOTA-TOC plus (177)Lu-DOTA-TOC in neuroendocrine cancers.","volume":"30","author":"Villard","year":"2012","journal-title":"J Clin Oncol"},{"key":"R42-5-20210204","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1507\/endocrj.48.95","article-title":"Immunohistochemical localization of somatostatin receptor type 2A in rat and human tissues.","volume":"48","author":"Kimura","year":"2001","journal-title":"Endocr J"},{"key":"R43-5-20210204","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1007\/s00259-009-1151-8","article-title":"Effects of therapy with Lu-177 DOTA 0,Tyr 3 DOTATATE on endocrine function.","volume":"36","author":"Teunissen","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R44-5-20210204","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1210\/jcem-70-4-944","article-title":"Serum gonadotropins and alpha-subunit decline in aging normal postmenopausal women.","volume":"70","author":"Kwekkeboom","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"R45-5-20210204","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1677\/joe.0.1690519","article-title":"Differential radiosensitivity of hypothalamo-pituitary function in the young adult rat.","volume":"169","author":"Robinson","year":"2001","journal-title":"J Endocrinol"},{"key":"R46-5-20210204","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2307\/3575908","article-title":"The effect of single-dose radiation on cell survival and growth hormone secretion by rat anterior pituitary cells.","volume":"94","author":"Hochberg","year":"1983","journal-title":"Radiat Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0b013e3182814ac1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:28:21Z","timestamp":1621884501000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201303000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0b013e3182814ac1","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}